Lexaria Bioscience Corp LEXX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Lexaria Enters a New Pharmaceutical Agreement for DehydraTECH
Lexaria Celebrates its 70th Patent Award
Lexaria's Human Study GLP-1-H26-7 Reaches Full Enrollment and Continues Dosing on Schedule
Lexaria Announces Results from Animal Study GLP-1-A26-1
GLP-1 Weight-Loss/Diabetes Industries Continue Transition to Oral Medications
Lexaria Updates Financial Position
Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds
Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds
Trading Information
- Previous Close Price
- $4.17
- Day Range
- $4.13–4.13
- 52-Week Range
- $2.45–21.45
- Bid/Ask
- $3.83 / $4.22
- Shares Outstanding
- 2.11M
- Market Cap
- $8.78M
- Volume/Avg
- 254 / 73,078
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 32.32
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 7
Valuation
Metric | LEXX |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.45 |
Price/Sales | 32.32 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | LEXX |
|---|---|
Quick Ratio | 9.56 |
Current Ratio | 10.60 |
Interest Coverage | — |
Quick Ratio
LEXX
Profitability
Metric | LEXX |
|---|---|
Return on Assets (Normalized) | −126.22% |
Return on Equity (Normalized) | −143.73% |
Return on Invested Capital (Normalized) | −152.70% |
Return on Assets
LEXX
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|M<^zy% | LOCK|@SJw | $138B | |||
| Moderna Inc MRNA | LOCK|$wy!MGk | LOCK|Lj | $96B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|Xpn#!n^ | LOCK|&RB>> | $93B | |||
| argenx SE ADR ARGX | LOCK|&>vm><l | LOCK|T<V | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|l#@Wg>% | LOCK|!!P | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|gkltC%kd | LOCK|K?%L< | $30B | |||
| Incyte Corp INCY | LOCK|K?MBH! | LOCK|F@ | $24B | |||
| BioNTech SE ADR BNTX | LOCK|ssFq<# | LOCK|Mx | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|?s#<?$X | LOCK|%>pV | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|k<B%M? | LOCK|M# | $15B |
United States